CN1379777A - 氨基－三唑并吡啶衍生物 - Google Patents

氨基－三唑并吡啶衍生物 Download PDF

Info

Publication number
CN1379777A
CN1379777A CN00812501A CN00812501A CN1379777A CN 1379777 A CN1379777 A CN 1379777A CN 00812501 A CN00812501 A CN 00812501A CN 00812501 A CN00812501 A CN 00812501A CN 1379777 A CN1379777 A CN 1379777A
Authority
CN
China
Prior art keywords
triazolo
phenyl
pyridin
pyridine
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00812501A
Other languages
English (en)
Chinese (zh)
Inventor
G·休伯特罗逖曼
W·亨克勒
R·雅各布-劳特恩
G·J·基尔帕特里克
M·H·内蒂克温
C·里迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1379777A publication Critical patent/CN1379777A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN00812501A 1999-09-06 2000-08-28 氨基－三唑并吡啶衍生物 Pending CN1379777A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99117578.7 1999-09-06
EP99117578 1999-09-06

Publications (1)

Publication Number Publication Date
CN1379777A true CN1379777A (zh) 2002-11-13

Family

ID=8238933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00812501A Pending CN1379777A (zh) 1999-09-06 2000-08-28 氨基－三唑并吡啶衍生物

Country Status (22)

Country Link
US (1) US6355653B1 (cg-RX-API-DMAC7.html)
EP (1) EP1214322A2 (cg-RX-API-DMAC7.html)
JP (1) JP2003528811A (cg-RX-API-DMAC7.html)
KR (1) KR20020027625A (cg-RX-API-DMAC7.html)
CN (1) CN1379777A (cg-RX-API-DMAC7.html)
AR (1) AR037484A1 (cg-RX-API-DMAC7.html)
AU (1) AU7511000A (cg-RX-API-DMAC7.html)
BR (1) BR0013792A (cg-RX-API-DMAC7.html)
CA (1) CA2383998A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20021220A3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020172A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0203316A3 (cg-RX-API-DMAC7.html)
IL (1) IL148167A0 (cg-RX-API-DMAC7.html)
MA (1) MA26816A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02001748A (cg-RX-API-DMAC7.html)
NO (1) NO20021077L (cg-RX-API-DMAC7.html)
PE (1) PE20010629A1 (cg-RX-API-DMAC7.html)
PL (1) PL354240A1 (cg-RX-API-DMAC7.html)
TR (1) TR200200579T2 (cg-RX-API-DMAC7.html)
WO (1) WO2001017999A2 (cg-RX-API-DMAC7.html)
YU (1) YU13502A (cg-RX-API-DMAC7.html)
ZA (1) ZA200201055B (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
CN102439009A (zh) * 2009-05-12 2012-05-02 杨森制药有限公司 7-芳基-1，2，4-三唑并[4，3-a]吡啶衍生物及其作为MGLUR2受体的正向变构性调节剂的用途
CN102471337A (zh) * 2009-07-17 2012-05-23 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
CN103827114A (zh) * 2011-09-19 2014-05-28 霍夫曼-拉罗奇有限公司 作为pde10a抑制剂的三唑并吡啶化合物
CN106543175A (zh) * 2016-10-28 2017-03-29 上海大学 三芳基[1,2,4]三氮唑[1,5‑a]吡啶衍生物及其制备方法
TWI772386B (zh) * 2017-03-16 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用
CN115867553A (zh) * 2021-01-09 2023-03-28 巴格沃克斯研究有限公司 作为腺苷2A受体和腺苷2B受体拮抗剂的二氨基吡唑[1,5-a]并嘧啶-6-腈化合物
CN116082335A (zh) * 2023-01-16 2023-05-09 上海凌凯医药科技有限公司 一种二芳基醚化合物的制备方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506772B1 (en) * 2000-12-15 2003-01-14 Hoffmann-La Roche Inc. Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
MXPA04003277A (es) * 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
ATE358130T1 (de) 2001-11-30 2007-04-15 Schering Corp Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
KR101166000B1 (ko) 2002-01-28 2012-07-16 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
WO2003106446A1 (en) * 2002-06-13 2003-12-24 Pfizer Inc. Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
US20080033006A1 (en) * 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
MX2007007604A (es) * 2004-12-21 2007-08-02 Schering Corp Antagonistas del receptor de pirazolo[1,5-a]pirimidina adenosina a2a.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
JP5030114B2 (ja) * 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
EA018036B1 (ru) * 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
US7977352B2 (en) 2006-12-01 2011-07-12 Galapagos Nv Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
EA200970931A1 (ru) * 2007-04-10 2010-04-30 Х. Лундбекк А/С Аналоги гетероариламидов
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5492092B2 (ja) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2283001A2 (en) * 2008-05-13 2011-02-16 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
CN102131390A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
EP2326629B1 (en) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
BRPI0919172A2 (pt) * 2008-09-25 2015-12-15 Boehringer Ingelheim Int compostos os quais modulam seletivamente o receptor de cb2
NZ597140A (en) 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (en) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN109071444A (zh) 2016-03-16 2018-12-21 拜耳作物科学股份公司 作为农药和植物保护剂的n-(氰苄基)-6-(环丙基-羰基氨基)-4-(苯基)-吡啶-2-羧酰胺衍生物及相关化合物
CR20230030A (es) 2018-02-27 2023-03-10 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN117304191A (zh) * 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
WO2020054712A1 (ja) * 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤
IL318278A (en) 2018-12-20 2025-03-01 Incyte Corp Imidazopyridazine and imidazopyridine compounds and their use
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
CN102439009A (zh) * 2009-05-12 2012-05-02 杨森制药有限公司 7-芳基-1，2，4-三唑并[4，3-a]吡啶衍生物及其作为MGLUR2受体的正向变构性调节剂的用途
CN102439009B (zh) * 2009-05-12 2014-11-12 杨森制药有限公司 7-芳基-1，2，4-三唑并[4，3-a]吡啶衍生物及其作为MGLUR2受体的正向变构性调节剂的用途
CN102471337A (zh) * 2009-07-17 2012-05-23 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
CN103827114A (zh) * 2011-09-19 2014-05-28 霍夫曼-拉罗奇有限公司 作为pde10a抑制剂的三唑并吡啶化合物
CN103827114B (zh) * 2011-09-19 2016-08-24 霍夫曼-拉罗奇有限公司 作为pde10a抑制剂的三唑并吡啶化合物
CN106543175A (zh) * 2016-10-28 2017-03-29 上海大学 三芳基[1,2,4]三氮唑[1,5‑a]吡啶衍生物及其制备方法
TWI772386B (zh) * 2017-03-16 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基并[4,3-c]嘧啶-5-胺類衍生物、其製備方法及其在醫藥上的使用
CN115867553A (zh) * 2021-01-09 2023-03-28 巴格沃克斯研究有限公司 作为腺苷2A受体和腺苷2B受体拮抗剂的二氨基吡唑[1,5-a]并嘧啶-6-腈化合物
CN116082335A (zh) * 2023-01-16 2023-05-09 上海凌凯医药科技有限公司 一种二芳基醚化合物的制备方法

Also Published As

Publication number Publication date
KR20020027625A (ko) 2002-04-13
YU13502A (sh) 2004-11-25
CZ20021220A3 (cs) 2002-10-16
JP2003528811A (ja) 2003-09-30
TR200200579T2 (tr) 2002-12-23
IL148167A0 (en) 2002-09-12
AR037484A1 (es) 2004-11-17
PE20010629A1 (es) 2001-05-30
WO2001017999A2 (en) 2001-03-15
NO20021077D0 (no) 2002-03-05
BR0013792A (pt) 2002-05-14
MA26816A1 (fr) 2004-12-20
CA2383998A1 (en) 2001-03-15
HRP20020172A2 (en) 2003-10-31
US6355653B1 (en) 2002-03-12
WO2001017999A3 (en) 2001-12-06
NO20021077L (no) 2002-03-05
MXPA02001748A (es) 2002-08-06
PL354240A1 (en) 2003-12-29
EP1214322A2 (en) 2002-06-19
AU7511000A (en) 2001-04-10
ZA200201055B (en) 2003-07-30
HUP0203316A2 (hu) 2003-01-28
HUP0203316A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
CN1379777A (zh) 氨基－三唑并吡啶衍生物
CN1166666C (zh) 缩合咪唑化合物和治疗糖尿病的药物
CN1239485C (zh) 作为IL－1β和TNF－α抑制剂的二苯酮类
CN1144791C (zh) 三唑化合物及其作为多巴胺d3配体的应用
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1305862C (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1671696A (zh) 激酶抑制剂
CN1703405A (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1901917A (zh) 作为糖原磷酸化酶抑制剂用于治疗糖尿病和肥胖症的(3－氧代－3，4－二氢－喹喔啉－2－基－氨基)－苯甲酰胺衍生物和相关化合物
CN1741999A (zh) 用作GSK－3β抑制剂的哒嗪酮衍生物
CN1378542A (zh) 抗原结合片段i抑制剂
CN1270959A (zh) 4－苯基－吡啶衍生物
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
HK1040712A1 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
CN1823064A (zh) 用于治疗与gsk3有关的病症的2－芳基氨基－嘧啶
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1656082A (zh) 蛋白激酶抑制剂
CN1906190A (zh) 选择性激酶抑制剂
CN1761671A (zh) 用作PDE7抑制剂的4－氨基噻吩并[2,3－d]嘧啶－6－甲腈衍生物
CN1871244A (zh) 作为腺苷受体配体的噻唑并吡啶衍生物
CN1129702A (zh) 咪唑并吡啶
CN1751044A (zh) 用作pepck抑制剂的磺酰胺取代的黄嘌呤
CN101056875A (zh) 被取代的苯基氨基噻唑类化合物以及其应用
CN1053658C (zh) 氨基芪唑衍生物和药

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned